New agents in development for the treatment of bacterial infections
Darren Abbanat1, Brian Morrow, Karen Bush
1Johnson & Johnson Pharmaceutical Research and Development, L.L.C. 1000 Rte. 202, Raritan, NJ 08869, USA.
Abstract:
New antibacterial agents to treat infections caused by antibiotic-susceptible and antibiotic-resistant pathogens are in various stages of clinical development. In this review are compounds with demonstrated activity against methicillin-resistant staphylococci including investigational cephalosporins, carbapenems, and a new tetracycline, as well as glycopeptides effective against vancomycin-resistant enterococci (VRE), and fluoroquinolones with improved potency against respiratory pathogens and multidrug-resistant Gram-positive bacteria. Although most recent progress has occurred in the identification of agents for Gram-positive infections, broad-spectrum carbapenems are described for the treatment of multidrug-resistant Gram-negative pathogens. Also discussed are agents with mechanisms of action other than inhibition of protein synthesis, penicillin-binding proteins, and DNA topoisomerases; among these are inhibitors of bacterial fatty acid biosynthesis, peptidoglycan synthesis, and dihydrofolate reductase.
Related Concept Videos
Development of Antibiotic Resistance
Production of Antibiotics
Inhibitors of Bacterial Protein Synthesis
Microorganisms in Medicine and Therapeutics
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis


